Epic Sciences, Inc. today announced the appointment of Joel Smith as its chief financial officer and general counsel. Mr. Smith joins the company’s impressive roster of industry veterans.
Read More
Epic Sciences, Inc. (Epic) today announced that Lloyd Sanders has joined the company as president and chief executive officer. After serving nearly six years in the role, Murali Prahalad, Ph.D., has stepped down to pursue new opportunities and has been appointed to Epic’s board of directors.
Read More
Epic Sciences, Inc. announced today that it has named Chockalingam “Palani” Palaniappan as its new chief technology officer (CTO) to help the company advance its Functional Cell Profiling technology to drive global expansion. In his new role, Dr. Palaniappan will lead the vision for building a globally deployable, regulated platform for routine use of clinical applications for a range of cancer indications, as well as enabling drug discovery in biopharmaceutical industries. This new addition adds another life science veteran from global diagnostics and clinical drug development industries to the company’s executive management team.
Read More
Epic Sciences, Inc. announced today the appointment of Richard J. Wenstrup, M.D. as chief medical officer. In this role, Dr. Wenstrup will lead clinical development, regulatory and medical affairs strategies for the company and be responsible for advancing the company’s clinical research and product development pipeline.
Read More
New York-based Blue Ox Healthcare Partners (Blue Ox) is a private equity investment firm providing capital to growth stage healthcare companies. The firm focuses on businesses in the middle market targeting the industry’s transformation to individuality and value-based care in healthcare services, HCIT, and medical and life sciences technologies, whose innovations, strategies and operations are poised for growth.
Read More
Blue Ox Healthcare Partners, LLC (“Blue Ox” or the “Firm”), an investment firm focused on providing growth capital to healthcare companies in the middle market, today announced that it led a $52 million Series E investment in Epic Sciences, Inc. (“Epic”), a leading diagnostics company developing novel solutions to personalize and advance cancer treatment and management. Proceeds from the fundraising round are expected to be used to accelerate Epic’s clinical studies for oncology decision support services in its pipeline and execution of its long-term growth plan.
Read More